We collaborate with the report on personalized medicine from the Roche Institute.

The main researcher of the Neurodeath Unit Laboratory, of the Faculty of Medicine of the Castilla La Mancha University and responsible for the implementation of the Complementary Biotechnology Plan in Castilla-La Mancha, to which this group belongs, Valentín Ceña, has participated in the report “ Pharmacological Research in the Era of Personalized Precision Medicine ”, prepared by the Roche Institute.

The Anticipando Reports, prepared within the framework of the Observatory of Trends in Future Medicine promoted by the Roche Institute Foundation, arise with the objective of contributing to the generation and sharing of advances in areas of emerging knowledge related to personalized medicine of precision and that will be part of the medicine of the future.

This recently published report, in which Ceña has participated, is coordinated by Mabel Loza, Professor of Pharmacology at the University of Santiago de Compostela and Coordinator of the BioFarma Research group. In addition, experts such as Joan Albanell, Head of the Medical Oncology Service at the Hospital del Mar and Head of the Oncology Service at the HM Delfos Hospital in Barcelona, and María Jesús Blanco, Vice President of Chemical Sciences of the Medical Chemistry Division, have also participated in its preparation. in Atavistik Bio, Cambridge Massachusetts.

“This report addresses a series of different challenges that pharmacological research must address in the future to integrate all the tools and technological advances that already exist and/or are being developed, such as genomic sequencing, digitalization and artificial intelligence. to advance within the framework of Personalized Precision Medicine,” explains Valentín Ceña.

Personalized precision medicine seeks to offer the most appropriate, effective and safe treatment for each patient, taking into account their individual characteristics. To achieve this, it is necessary to change the approach, not only in the clinical practice approach to diseases, but throughout the entire pharmacological research process, from the early stages of research and development of new innovative treatments.

According to this Report, pharmacological research is experiencing a revolution making use of all the tools and technological advances available within the framework of personalized precision medicine, such as genomic sequencing , as well as the use of knowledge derived from the analysis of massive data and artificial intelligence tools .

In this way, it is possible to identify not only genetic predispositions to diseases , but also individual responses to pharmacological treatments based on the genomic profile and biomarkers that will facilitate the personalization of medications, minimizing side effects and optimizing their effectiveness.

Thus, trends in basic and preclinical research are aimed at the development of new strategies for the identification of targets and therapeutic mechanisms and the identification of new molecules and drugs.